These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 9053484

  • 1. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.
    Viladiu P, Bosch FX, Castellsagué X, Muñoz N, Escribà JM, Hamsíkova E, Hofmannova V, Guerrero E, Izquierdo A, Navarro C, Moreo P, Izarzugaza I, Ascunce N, Gili M, Muñoz MT, Tafur L, Shah KV, Vonka V.
    J Clin Oncol; 1997 Feb; 15(2):610-9. PubMed ID: 9053484
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer.
    Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Gallee MP, Hart AA, Müller M, Trimbos JB, Helmerhorst TJ.
    Cancer; 1994 Oct 15; 74(8):2307-13. PubMed ID: 7922982
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.
    Burger RA, Monk BJ, Kurosaki T, Anton-Culver H, Vasilev SA, Berman ML, Wilczynski SP.
    J Natl Cancer Inst; 1996 Oct 02; 88(19):1361-8. PubMed ID: 8827013
    [Abstract] [Full Text] [Related]

  • 5. HPV-16-related proteins as the serologic markers in cervical neoplasia.
    Park JS, Park DC, Kim CJ, Ahn HK, Um SJ, Park SN, Kim SJ, Namkoong SE.
    Gynecol Oncol; 1998 Apr 02; 69(1):47-55. PubMed ID: 9570998
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N.
    J Pathol; 1999 Sep 02; 189(1):12-9. PubMed ID: 10451482
    [Abstract] [Full Text] [Related]

  • 9. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
    de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX, Retrospective International Survey and HPV Time Trends Study Group.
    Lancet Oncol; 2010 Nov 02; 11(11):1048-56. PubMed ID: 20952254
    [Abstract] [Full Text] [Related]

  • 10. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
    Zumbach K, Kisseljov F, Sacharova O, Shaichaev G, Semjonova L, Pavlova L, Pawlita M.
    Int J Cancer; 2000 Feb 01; 85(3):313-8. PubMed ID: 10652419
    [Abstract] [Full Text] [Related]

  • 11. Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies.
    Baay MF, Duk JM, Groenier KH, Burger MP, de Bruijn HW, Hollema H, Stolz E, Herbrink P.
    Cancer Immunol Immunother; 1997 Jun 01; 44(4):211-5. PubMed ID: 9222279
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer.
    Fisher SG, Benitez-Bribiesca L, Nindl I, Stockfleth E, Muller M, Wolf H, Perez-Garcia F, Guzman-Gaona J, Gutierrez-Delgado F, Irvin W, Gissmann L.
    Gynecol Oncol; 1996 Apr 01; 61(1):73-8. PubMed ID: 8626121
    [Abstract] [Full Text] [Related]

  • 14. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
    Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL.
    Cancer; 2002 Apr 15; 94(8):2199-210. PubMed ID: 12001118
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later.
    Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E, Koskela P, Luostarinen T, Paavonen J, Pukkala E, Sigstad E, Thoresen S, Dillner J.
    Am J Obstet Gynecol; 2003 Jan 15; 188(1):49-55. PubMed ID: 12548195
    [Abstract] [Full Text] [Related]

  • 18. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil.
    Sun Y, Eluf-Neto J, Bosch FX, Muñoz N, Booth M, Walboomers JM, Shah KV, Viscidi RP.
    Cancer Epidemiol Biomarkers Prev; 1994 Jun 15; 3(4):341-7. PubMed ID: 8061584
    [Abstract] [Full Text] [Related]

  • 19. A new marker based on risk stratification of human papillomavirus DNA and tumor size to predict survival of locally advanced cervical cancer.
    Huang Y, He Q, Xu K, Zhou J, Yin J, Li F, Feng M, Lang J.
    Int J Gynecol Cancer; 2019 Mar 15; 29(3):459-465. PubMed ID: 30733276
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.